{"id":"allo-quadcar01-t","_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"Allo-QuadCAR01-T uses donor-derived T cells modified to express four different chimeric antigen receptors (CARs), enabling recognition of multiple tumor surface markers. This multi-targeting approach may reduce tumor escape and improve efficacy compared to single-target CAR-T therapies.","oneSentence":"Allogeneic CAR-T cells engineered to target four tumor-associated antigens simultaneously for enhanced cancer cell recognition and elimination."},"_scrapedAt":"2026-03-28T03:21:13.292Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123520,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"tisagenlecleucel","brand":"Kymriah","company":"Novartis","rationale":"Autologous CAR-T therapy for hematologic malignancies"},{"name":"axicabtagene ciloleucel","brand":"Yescarta","company":"Gilead/Kite","rationale":"Autologous CAR-T therapy competing in similar indications"},{"name":"ALLO-501","brand":null,"company":"Allogene Therapeutics","rationale":"Allogeneic CAR-T therapy offering off-the-shelf approach"}],"description":"Allo-QuadCAR01-T is an investigational allogeneic CAR-T cell therapy developed by AvenCell Therapeutics. As an off-the-shelf cellular immunotherapy, it is designed to target multiple antigens simultaneously, potentially offering broader cancer cell recognition while reducing manufacturing time compared to autologous CAR-T approaches.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT07474051","phase":"","title":"Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials","status":"ENROLLING_BY_INVITATION","sponsor":"AvenCell Therapeutics, Inc.","startDate":"2026-01-29","conditions":"B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy","enrollment":178},{"nctId":"NCT07284433","phase":"PHASE1, PHASE2","title":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","status":"RECRUITING","sponsor":"AvenCell Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse","enrollment":178}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Allo-QuadCAR01-T","genericName":"Allo-QuadCAR01-T","companyName":"AvenCell Therapeutics, Inc.","companyId":"avencell-therapeutics-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}